Of the 313 million surgical procedures undertaken worldwide annually, solely 6% happen within the poorest international locations, the place over a 3rd of the world’s inhabitants lives. That factoid is from an ideal report by The Lancet which postulates that democratized surgical availability ought to end in 5,000 surgical procedures for each 100,000 individuals yearly. That’s about 425 million surgical procedures a 12 months minimal with sufficient protection. At $10,000 a pop, that’s a couple of $4 trillion market. Why not construct a bunch of robots to carry out these surgical procedures and harvest {dollars} alongside organs?
TAM vs. SAM
Let’s begin with an important idea – total addressable market or TAM. Whereas the worldwide TAM for surgical procedures could also be large, the variety of surgical procedures that may be carried out by robotic options is far smaller. Robots excel in elective, precision-driven, minimally invasive soft-tissue instances which symbolize about 5% of surgical quantity – roughly 20 million procedures. So, the TAM for robotic surgical procedures sits at solely 20 million annual procedures.
Now, what number of of those procedures could be carried out by the main robotic surgical platform on the market – Intuitive Surgical $ISRG? About 9 million procedures yearly, and that’s known as a serviceable addressable market or SAM. In 2025, ISRG accomplished about 3 million procedures so that they’re at the moment capturing about 30% of the market they could possibly be capturing. Meaning there’s loads of room to develop, however we additionally want to think about the competitors which is slowly encroaching on their area.
Immediately, we need to attempt to reply three questions:
- Given the above assumptions, how a lot progress does ISRG have left, assuming their SAM doesn’t broaden whereas contemplating aggressive threats?
- What would it not take for them to handle the extra 11 million procedures they’re not in a position to handle now (TAM minus SAM)?
- What’s the chance that robotic surgical procedure platforms as a complete can transfer past simply 5% applicability they get pleasure from as we speak?
Merely put, may this $160 billion firm ever eclipse a trillion-dollar valuation?
Rising Competitors
ISRG’s sturdy gross margins, pushed by 84% recurring revenues, coupled with double-digit income progress, imply the corporate is richly priced – a present easy valuation ratio of 14 – however decrease than the historic common of 18.
That’s as a result of worldwide da Vinci process progress is predicted to be within the vary of 13% to fifteen%, down from the 18% progress noticed in 2025. (The corporate gives process progress steering, not income progress steering.) Causes for the slowdown vary from regulatory hurdles in worldwide markets to capability concerns to aggressive pressures. Nonetheless, the experiences of ISRG’s dying by rising opponents are vastly exaggerated.
The closest competitor when it comes to procedures carried out could be privately-held CMR, which has now handled 45,000 sufferers in complete – about what Intuitive does in 5 days. CMR is simply beginning U.S. commercialization following FDA approval late final 12 months. Different corporations are rolling out robotic surgical procedure options, however they’re focusing on a unique area of interest: orthopedic surgical procedure versus soft-tissue surgical procedure. For instance, medical gadget chief Stryker $SYK has accomplished 2 million knee and hip replacements with their Mako robotic, and Zimmer Biomet $ZBH claims their ROSA robotic is put in in over 2,000 hospitals for comparable use instances. Neither of those corporations are direct opponents to Intuitive. A detailed peer may be Medtronic $MDT with their Hugo robotic, however the firm doesn’t get away what number of procedures have really been carried out. All we all know is it was a grand complete of roughly 10,000 again in 2024, so that they seemingly nonetheless don’t maintain a candle to Intuitive’s 3 million annual procedures.
We will safely say that competitors isn’t consuming Intuitive’s lunch but, as they nonetheless command 60-80% world market share in robot-assisted surgical procedure. However for the corporate to maintain scaling, they want a plan to handle new procedures and geographies.
Future Progress Prospects
Intuitive must continuously be increasing their choices to shut the hole between their 9 million annual process SAM and 20 million annual process TAM. The corporate believes future market share positive factors will come from three key areas:
- Elevated cardiac procedures
- Adoption by Ambulatory Surgery Centers (ASCs)
- Growth in Europe
In January of this 12 months, Intuitive acquired FDA approval for a restricted quantity of cardiac procedures together with mitral valve restore and IMA (internal mammary artery) mobilization for cardiac revascularization. This extra approval may open the door for an additional 160,000 annual procedures. That received’t transfer the needle a lot. Relating to ASCs, Intuitive realized these same-day surgical procedure facilities typically have decrease budgets than conventional hospitals, so that they’ve began providing used and refurbished da Vinci techniques of older fashions.
Lastly, their European growth seems to be within the early levels, however administration claims it grew 21% in 2025. That’s a bit greater than the 18% year-over-year progress in general “Exterior U.S.” income, however nonetheless beneath the 22% year-over-year progress that U.S. revenues confirmed in 2025. The 342 complete da Vinci techniques at the moment put in in Europe are a drop within the bucket in comparison with the 9,000 complete lively da Vinci techniques worldwide. We’d anticipate progress to be lots stronger off such a small base. Seems our pals abroad are usually a bit extra price-sensitive as a result of restricted hospital budgets. Costly surgical robots promote higher in ‘Murica because of capitalistic healthcare techniques. If Intuitive needs to see extra progress in Europe, they’ll have to decrease their costs and take a success on margins, or supply used and refurbished gadgets like they’re doing with ASCs.
Promoting extra merchandise to broaden their SAM comes right down to execution. However can the TAM for robotic surgical procedures broaden to greater than 5% of general surgical procedures, particularly given the developments we’re seeing in synthetic intelligence?
Increasing the TAM
Appears outstanding that solely 5% of all surgical procedures carried out worldwide could be carried out utilizing robotics platforms. Most surgeons are inquisitive about robotics, but adoption at the moment lags. That’s in keeping with a report by Bain that factors to “an absence of effectivity as a result of longer surgical procedure time” because the main trigger why robotics options aren’t being adopted. Higher outcomes simply aren’t sufficient to surpass that hurdle when confronted with “restricted scientific proof and excessive ongoing and up-front prices.” You even have “many procedures the place robots are nonetheless in growth or face technological obstacles.”
Up-front tools prices have been stated to be “a very powerful consideration when making a purchase order” and the third largest barrier to adoption. Having the ability to supply lower-cost platforms will open doorways to increasing the variety of procedures. Further worth may be added by means of “intra-operative gadget steering, AI-based planning, and different cutting-edge options” resembling 5G-enabled distant surgical procedures for rising markets the place expertise is briefly provide. As at all times, it comes right down to the almighty greenback. The 20 million process TAM could possibly be expanded have been price not an element. Expertise could assist handle these shortcomings, however ISRG can be increasing into diagnostics as a option to enhance their footprint with current shoppers.
In different phrases, why not promote adjoining merchandise because you’re already speaking to key choice makers in hospitals?
New Diagnostics Alternatives
Hospitals that may afford costly robotic surgical procedure platforms have deep pockets. That is the place Ion comes into play. Ion is Intuitive’s new endoluminal platform. Endoluminal merely refers back to the remedy of the tubes inside a human physique, issues like blood vessels and intestines. Ion is at the moment focusing on lung biopsy, or the elimination of lung cells to check for indicators of lung most cancers. Since lung most cancers is the main reason behind cancer-related dying, this opens up one other large alternative for Intuitive. As we’d anticipate, Ion procedures are rising rapidly, up 51% year-over-year in 2025 off an almost 100,000 process base.
Our first query was: “Why did it take so lengthy for Ion to achieve momentum?” The platform was launched in 2019 however solely noticed about 1,000 procedures in 2020. Quite than an absence of demand, this regular ramp-up was as a result of hospitals taking time to undergo the required hurdles of deploying the brand new system. Specialists wanted to coach themselves, and higher-ups wanted to approve new budgets to afford the $700,000 gadget.
We have been hoping Intuitive would have some grand plans to roll out different new diagnostic gadgets to broaden their addressable market, nevertheless it seems administration is extra targeted on decreasing the detection-to-treatment time. After that, the corporate could look to broaden Ion to incorporate remedy choices in addition to prognosis. Administration additionally hinted at increasing outdoors of lung most cancers into benign lung illness and COPD detection. The previous is quite common and never life-threatening, and the latter is a little more uncommon, affecting solely round 15 million Individuals. This hardly looks as if a significant growth, nevertheless it does present room for Intuitive to develop within the diagnostic area whereas remaining a frontrunner in robot-assisted surgical procedure.
The Trillion Greenback Query
For those who’re a $160 billion firm doing 3.2 million procedures a 12 months which generate $10 billion a 12 months, then all these numbers want to extend by an element of six to hit the trillion-dollar valuation. So about 20 million procedures a 12 months, which represents your complete complete addressable market. Filling the hole between SAM and TAM turns into necessary. So does conserving the competitors at bay. Maybe their foray into diagnostics can decide up some slack, however we are able to’t assume that pricing stays the identical. If a key barrier to adoption is price, they’ll ultimately have to cost much less to extend market share. Much less worthwhile companies command decrease valuations.
The place ISRG can complement their progress is thru adjoining choices that hospitals with deep pockets may discover compelling. In a previous go to to Stanford, we checked out how imaging applied sciences and augmented actuality are serving to surgeons make higher selections. If ISRG is already talking to key choice makers, it’s a lot simpler to cross-sell them different applied sciences that make a surgeon’s life simpler.
Finally, ISRG wants to make use of their da Vinci money cow correctly. With 9 billion in money and investments readily available, and one-third of that quantity generated final 12 months from constructive working money flows, buying bolt-on progress or investing closely in new platforms is what’s wanted to maintain progress on monitor ought to they ever hope to turn out to be the world’s largest healthcare firm.
Conclusion
Intuitive Surgical has seen income progress speed up for 3 years now, although this 12 months the forecasted process steering implies a slowdown in progress. Prospects cite price as a significant obstacle to adoption, and catering to these wishes means doubtlessly compressing their margins which makes the enterprise much less worthwhile. It’s a troublesome place to be in, however expertise could make the platform so helpful that hospitals can’t afford to not use it. Adjoining platforms and performance can complement progress, however in the end, we have to know that they’re in a position to seize the extra six million procedures of their SAM and in the end broaden into the extra ten million procedures of their TAM. We’ll examine again in a 12 months to see how issues are going.
